Publication date: Mar 06, 2019
Huntington’s disease is caused by an abnormally expanded CAG repeat expansion in the HTT gene, which confers a predominant toxic gain of function in the mutant huntingtin (mHTT) protein. There are currently no disease-modifying therapies available, but approaches that target proximally in disease pathogenesis hold great promise. These include DNA-targeting techniques such as zinc-finger proteins, transcription activator-like effector nucleases, and CRISPR/Cas9; post-transcriptional huntingtin-lowering approaches such as RNAi, antisense oligonucleotides, and small-molecule splicing modulators; and novel methods to clear the mHTT protein, such as proteolysis-targeting chimeras. Improvements in the delivery and distribution of such agents as well as the development of objective biomarkers of disease and of HTT lowering pharmacodynamic outcomes have brought these potential therapies to the forefront of Huntington’s disease research, with clinical trials in patients already underway.
Tabrizi, S.J., Ghosh, R., and Leavitt, B.R. Huntingtin Lowering Strategies for Disease Modification in Huntington’s Disease. 06385. 2019 Neuron (101):5.
- CRISPR-Cas9 in genome editing: Its function and medical applications.
- Huntington’s disease therapeutics conference 2019 – Day 1
- Huntington’s disease therapeutics conference 2019 – Day 2
- Fluid and imaging biomarkers for Huntington’s disease.
- Phase 3 Trial of RG6042 Will Gauge Potential of Gene-silencing Approaches for Huntington’s, Other Diseases